vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $18.6M, roughly 1.0× ENANTA PHARMACEUTICALS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -64.1%, a 129.9% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 9.8%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 4.5%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
ENTA vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $18.6M |
| Net Profit | $-11.9M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | -60.5% | 56.3% |
| Net Margin | -64.1% | 65.7% |
| Revenue YoY | 9.8% | 1808.5% |
| Net Profit YoY | 46.4% | 376.5% |
| EPS (diluted) | $-0.42 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $18.6M | ||
| Q3 25 | $15.1M | $334.0K | ||
| Q2 25 | $18.3M | $1.4M | ||
| Q1 25 | $14.9M | $257.0K | ||
| Q4 24 | $17.0M | $977.0K | ||
| Q3 24 | $14.6M | $660.0K | ||
| Q2 24 | $18.0M | $736.0K | ||
| Q1 24 | $17.1M | $1.4M |
| Q4 25 | $-11.9M | $12.3M | ||
| Q3 25 | $-18.7M | $-8.6M | ||
| Q2 25 | $-18.3M | $-6.9M | ||
| Q1 25 | $-22.6M | $-5.4M | ||
| Q4 24 | $-22.3M | — | ||
| Q3 24 | $-28.8M | $-2.8M | ||
| Q2 24 | $-22.7M | $-14.5M | ||
| Q1 24 | $-31.2M | $411.0K |
| Q4 25 | -60.5% | 56.3% | ||
| Q3 25 | -121.6% | -2516.5% | ||
| Q2 25 | -103.2% | -701.0% | ||
| Q1 25 | -164.3% | -3350.2% | ||
| Q4 24 | -138.8% | — | ||
| Q3 24 | -204.4% | -1563.6% | ||
| Q2 24 | -134.6% | -1255.0% | ||
| Q1 24 | -192.1% | -692.5% |
| Q4 25 | -64.1% | 65.7% | ||
| Q3 25 | -123.6% | -2572.2% | ||
| Q2 25 | -99.7% | -504.8% | ||
| Q1 25 | -151.7% | -2097.7% | ||
| Q4 24 | -131.4% | — | ||
| Q3 24 | -197.3% | -425.5% | ||
| Q2 24 | -126.1% | -1964.4% | ||
| Q1 24 | -182.7% | 29.9% |
| Q4 25 | $-0.42 | $0.25 | ||
| Q3 25 | $-0.88 | $-0.17 | ||
| Q2 25 | $-0.85 | $-0.14 | ||
| Q1 25 | $-1.06 | $-0.11 | ||
| Q4 24 | $-1.05 | — | ||
| Q3 24 | $-1.36 | $-0.06 | ||
| Q2 24 | $-1.07 | $-0.30 | ||
| Q1 24 | $-1.47 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $49.4M |
| Total Assets | $329.5M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | $40.0M | ||
| Q3 25 | $32.3M | $37.9M | ||
| Q2 25 | $44.8M | $44.8M | ||
| Q1 25 | $60.2M | $40.6M | ||
| Q4 24 | $84.3M | $59.3M | ||
| Q3 24 | $37.2M | $68.8M | ||
| Q2 24 | $35.8M | $73.0M | ||
| Q1 24 | $63.5M | $80.2M |
| Q4 25 | $126.6M | $49.4M | ||
| Q3 25 | $64.7M | $36.4M | ||
| Q2 25 | $79.3M | $44.5M | ||
| Q1 25 | $93.5M | $50.5M | ||
| Q4 24 | $111.8M | $55.1M | ||
| Q3 24 | $128.8M | $58.5M | ||
| Q2 24 | $148.9M | $60.4M | ||
| Q1 24 | $166.1M | $74.1M |
| Q4 25 | $329.5M | $59.0M | ||
| Q3 25 | $280.7M | $51.1M | ||
| Q2 25 | $301.0M | $60.7M | ||
| Q1 25 | $323.0M | $67.9M | ||
| Q4 24 | $348.6M | $90.6M | ||
| Q3 24 | $376.7M | $99.0M | ||
| Q2 24 | $398.8M | $107.8M | ||
| Q1 24 | $413.6M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $18.4M |
| Free Cash FlowOCF − Capex | $-11.8M | — |
| FCF MarginFCF / Revenue | -63.6% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $18.4M | ||
| Q3 25 | $-6.5M | $-8.7M | ||
| Q2 25 | $17.5M | $-7.5M | ||
| Q1 25 | $-13.5M | $-7.5M | ||
| Q4 24 | $-16.8M | $-24.0M | ||
| Q3 24 | $-10.4M | $765.0K | ||
| Q2 24 | $-14.8M | $-10.9M | ||
| Q1 24 | $-28.6M | $-4.0M |
| Q4 25 | $-11.8M | — | ||
| Q3 25 | $-7.9M | — | ||
| Q2 25 | $17.4M | — | ||
| Q1 25 | $-16.0M | — | ||
| Q4 24 | $-25.5M | — | ||
| Q3 24 | $-19.4M | — | ||
| Q2 24 | $-21.3M | — | ||
| Q1 24 | $-30.3M | — |
| Q4 25 | -63.6% | — | ||
| Q3 25 | -52.5% | — | ||
| Q2 25 | 94.7% | — | ||
| Q1 25 | -107.4% | — | ||
| Q4 24 | -150.6% | — | ||
| Q3 24 | -132.5% | — | ||
| Q2 24 | -118.6% | — | ||
| Q1 24 | -177.5% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 9.6% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 17.0% | — | ||
| Q4 24 | 51.6% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 36.4% | — | ||
| Q1 24 | 9.8% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENTA
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
